Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Drury

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|February 24, 2018
Bayesian joint modelling of benefit and risk in drug developmentMaria J Costa, Thomas Drury
Pharmaceutical Statistics|February 7, 2026
Using Off-Treatment Sequential Multiple Imputation for Binary Outcomes to Address Intercurrent Events Handled by a Treatment Policy StrategySunita Rehal, Nicky Best, Sarah Watts, et al.
Pharmaceutical Statistics|August 5, 2024
Estimation of Treatment Policy Estimands for Continuous Outcomes Using Off-Treatment Sequential Multiple ImputationThomas Drury, Juan J Abellan, Nicky Best, et al.
Pharmaceutical Statistics|August 23, 2025
The Estimand Framework and Causal Inference: Complementary Not Competing ParadigmsThomas Drury, Jonathan W Bartlett, David Wright, et al.
Pharmaceutical Statistics|January 8, 2022
Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatmentBenjamin Hartley, Thomas Drury, Sally Lettis, et al.
Journal of Biopharmaceutical Statistics|September 25, 2023
Comments on "Emerging insights and commentaries - MMRM vs LOCF by Naitee Ting"David Wright, Daniel J Bratton, Thomas Drury, et al.
Statistics in Medicine|February 14, 2025
Using Win Odds to Improve Commit-to-Phase-3 Decision-Making in OncologyBenjamin F Hartley, Thomas Drury, Brian Di Pace, et al.
Pharmaceutical Statistics|March 6, 2025
Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 TrialJames Bell, Thomas Drury, Tobias Mütze, et al.
American Journal of Respiratory and Critical Care Medicine|June 12, 2026
Defining disease stability in COPD: Evidence from Phase 3 clinical trialsDave Singh, Rianne Stacey, David M G Halpin, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|February 24, 2018
Bayesian joint modelling of benefit and risk in drug developmentMaria J Costa, Thomas Drury
Pharmaceutical Statistics|February 7, 2026
Using Off-Treatment Sequential Multiple Imputation for Binary Outcomes to Address Intercurrent Events Handled by a Treatment Policy StrategySunita Rehal, Nicky Best, Sarah Watts, et al.
Pharmaceutical Statistics|August 5, 2024
Estimation of Treatment Policy Estimands for Continuous Outcomes Using Off-Treatment Sequential Multiple ImputationThomas Drury, Juan J Abellan, Nicky Best, et al.
Pharmaceutical Statistics|August 23, 2025
The Estimand Framework and Causal Inference: Complementary Not Competing ParadigmsThomas Drury, Jonathan W Bartlett, David Wright, et al.
Pharmaceutical Statistics|January 8, 2022
Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatmentBenjamin Hartley, Thomas Drury, Sally Lettis, et al.
Journal of Biopharmaceutical Statistics|September 25, 2023
Comments on "Emerging insights and commentaries - MMRM vs LOCF by Naitee Ting"David Wright, Daniel J Bratton, Thomas Drury, et al.
Statistics in Medicine|February 14, 2025
Using Win Odds to Improve Commit-to-Phase-3 Decision-Making in OncologyBenjamin F Hartley, Thomas Drury, Brian Di Pace, et al.
Pharmaceutical Statistics|March 6, 2025
Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 TrialJames Bell, Thomas Drury, Tobias Mütze, et al.
American Journal of Respiratory and Critical Care Medicine|June 12, 2026
Defining disease stability in COPD: Evidence from Phase 3 clinical trialsDave Singh, Rianne Stacey, David M G Halpin, et al.
Pageof 1